Loading...

BioHiTech Global

Nasdaq:BHTG
Snowflake Description

High growth potential and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BHTG
Nasdaq
$27M
Market Cap
  1. Home
  2. US
  3. Commercial Services
Company description

BioHiTech Global, Inc., through its subsidiaries, provides technological, biological, and mechanical engineering solutions for the control, reduction, and/or reuse of organic and municipal waste worldwide. The last earnings update was 68 days ago. More info.


Add to Portfolio Compare Print
  • BioHiTech Global has significant price volatility in the past 3 months.
BHTG Share Price and Events
7 Day Returns
2.5%
NasdaqCM:BHTG
0.5%
US Commercial Services
-1.2%
US Market
1 Year Returns
-49.1%
NasdaqCM:BHTG
10.5%
US Commercial Services
3.4%
US Market
BHTG Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BioHiTech Global (BHTG) 2.5% -4.3% -31.7% -49.1% -47.1% -
US Commercial Services 0.5% -0.1% 4.8% 10.5% 51% 80.6%
US Market -1.2% 0.7% 1.7% 3.4% 35.5% 41.6%
1 Year Return vs Industry and Market
  • BHTG underperformed the Commercial Services industry which returned 10.5% over the past year.
  • BHTG underperformed the Market in United States of America which returned 3.4% over the past year.
Price Volatility
BHTG
Industry
5yr Volatility vs Market

Value

 Is BioHiTech Global undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of BioHiTech Global to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for BioHiTech Global.

NasdaqCM:BHTG Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10.4%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqCM:BHTG
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Commercial Services Unlevered Beta Simply Wall St/ S&P Global 0.67
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.672 (1 + (1- 21%) (144.18%))
1.293
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.29
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.293 * 5.96%)
10.44%

Discounted Cash Flow Calculation for NasdaqCM:BHTG using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for BioHiTech Global is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqCM:BHTG DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 10.44%)
2020 -2.00 Analyst x1 -1.81
2021 3.60 Analyst x1 2.95
2022 5.89 Est @ 63.72% 4.38
2023 8.57 Est @ 45.42% 5.76
2024 11.37 Est @ 32.61% 6.92
2025 14.05 Est @ 23.65% 7.75
2026 16.50 Est @ 17.37% 8.23
2027 18.64 Est @ 12.98% 8.42
2028 20.48 Est @ 9.9% 8.38
2029 22.07 Est @ 7.75% 8.18
Present value of next 10 years cash flows $59.16
NasdaqCM:BHTG DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $22.07 × (1 + 2.73%) ÷ (10.44% – 2.73%)
$294.22
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $294.22 ÷ (1 + 10.44%)10
$109.03
NasdaqCM:BHTG Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $59.16 + $109.03
$168.20
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $168.20 / 14.91
$11.28
NasdaqCM:BHTG Discount to Share Price
Calculation Result
Value per share (USD) From above. $11.28
Current discount Discount to share price of $1.80
= -1 x ($1.80 - $11.28) / $11.28
84%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price BioHiTech Global is available for.
Intrinsic value
>50%
Share price is $1.8 vs Future cash flow value of $11.28
Current Discount Checks
For BioHiTech Global to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • BioHiTech Global's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • BioHiTech Global's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BioHiTech Global's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BioHiTech Global's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:BHTG PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.82
NasdaqCM:BHTG Share Price ** NasdaqCM (2019-07-19) in USD $1.8
United States of America Commercial Services Industry PE Ratio Median Figure of 46 Publicly-Listed Commercial Services Companies 22.93x
United States of America Market PE Ratio Median Figure of 3,081 Publicly-Listed Companies 17.87x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BioHiTech Global.

NasdaqCM:BHTG PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:BHTG Share Price ÷ EPS (both in USD)

= 1.8 ÷ -0.82

-2.2x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioHiTech Global is loss making, we can't compare its value to the US Commercial Services industry average.
  • BioHiTech Global is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does BioHiTech Global's expected growth come at a high price?
Raw Data
NasdaqCM:BHTG PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.2x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
104.5%per year
United States of America Commercial Services Industry PEG Ratio Median Figure of 34 Publicly-Listed Commercial Services Companies 1.64x
United States of America Market PEG Ratio Median Figure of 2,119 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for BioHiTech Global, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BioHiTech Global's assets?
Raw Data
NasdaqCM:BHTG PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $-0.19
NasdaqCM:BHTG Share Price * NasdaqCM (2019-07-19) in USD $1.8
United States of America Commercial Services Industry PB Ratio Median Figure of 86 Publicly-Listed Commercial Services Companies 1.83x
United States of America Market PB Ratio Median Figure of 5,247 Publicly-Listed Companies 1.79x
NasdaqCM:BHTG PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:BHTG Share Price ÷ Book Value per Share (both in USD)

= 1.8 ÷ -0.19

-9.52x

* Primary Listing of BioHiTech Global.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioHiTech Global has negative assets, we can't compare the value of its assets to the US Commercial Services industry average.
X
Value checks
We assess BioHiTech Global's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Commercial Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Commercial Services industry average (and greater than 0)? (1 check)
  5. BioHiTech Global has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is BioHiTech Global expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
104.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BioHiTech Global expected to grow at an attractive rate?
  • BioHiTech Global's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • BioHiTech Global's earnings growth is expected to exceed the United States of America market average.
  • BioHiTech Global's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:BHTG Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:BHTG Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 104.5%
NasdaqCM:BHTG Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 46%
United States of America Commercial Services Industry Earnings Growth Rate Market Cap Weighted Average 15.4%
United States of America Commercial Services Industry Revenue Growth Rate Market Cap Weighted Average 5.3%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:BHTG Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:BHTG Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 18 6 4 1
2020-12-31 17 2 4 1
2019-12-31 9 0 -2 1
NasdaqCM:BHTG Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 3 -5 -12
2018-12-31 3 -6 -15
2018-09-30 3 -5 -15
2018-06-30 3 -6 -15
2018-03-31 2 -6 -12
2017-12-31 2 -5 -8
2017-09-30 3 -5 -8
2017-06-30 2 -4 -7
2017-03-31 2 -5 -7
2016-12-31 2 -5 -7
2016-09-30 2 -5 -7
2016-06-30 2 -5 -7

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • BioHiTech Global's earnings are expected to grow significantly at over 20% yearly.
  • BioHiTech Global's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:BHTG Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from BioHiTech Global Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:BHTG Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 0.28 0.28 0.28 1.00
2020-12-31 0.25 0.25 0.25 1.00
2019-12-31 -0.11 -0.11 -0.11 1.00
NasdaqCM:BHTG Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.82
2018-12-31 -1.11
2018-09-30 -1.24
2018-06-30 -1.44
2018-03-31 -1.26
2017-12-31 -0.98
2017-09-30 -0.96
2017-06-30 -0.89
2017-03-31 -0.87
2016-12-31 -0.82
2016-09-30 -0.83
2016-06-30 -0.84

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if BioHiTech Global will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess BioHiTech Global's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BioHiTech Global has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has BioHiTech Global performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BioHiTech Global's growth in the last year to its industry (Commercial Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BioHiTech Global does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare BioHiTech Global's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare BioHiTech Global's 1-year growth to the US Commercial Services industry average as it is not currently profitable.
Earnings and Revenue History
BioHiTech Global's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BioHiTech Global Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:BHTG Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 3.45 -11.93 7.49
2018-12-31 3.36 -15.16 6.74
2018-09-30 3.27 -15.22 5.95 0.82
2018-06-30 2.84 -15.40 6.06 0.81
2018-03-31 2.48 -11.64 7.05 -0.19
2017-12-31 2.42 -8.36 7.19
2017-09-30 2.50 -7.99 6.86 0.24
2017-06-30 2.47 -7.33 5.90 0.88
2017-03-31 2.37 -7.17 5.84 0.90
2016-12-31 2.24 -6.75 5.49 0.90
2016-09-30 2.11 -6.82 5.66 0.87
2016-06-30 1.83 -6.64 5.47 0.80
2016-03-31 1.70 -5.64 4.77 0.71
2015-12-31 1.51 -5.00 4.07 0.70
2015-09-30 1.48 -4.59 3.13 1.07
2015-06-30 1.62 -3.85 2.71 0.90
2015-03-31 1.55 -3.90 2.75 0.76
2014-12-31 1.52 -3.70 2.79 0.58
2014-09-30 2.70 -2.71 3.02
2014-06-30 3.94 -2.44 3.17
2014-03-31 3.69 -1.67 2.48
2013-12-31 3.44 -0.90 1.78

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if BioHiTech Global has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if BioHiTech Global has efficiently used its assets last year compared to the US Commercial Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if BioHiTech Global improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess BioHiTech Global's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Commercial Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BioHiTech Global has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is BioHiTech Global's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BioHiTech Global's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BioHiTech Global's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • BioHiTech Global's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of BioHiTech Global's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BioHiTech Global Company Filings, last reported 3 months ago.

NasdaqCM:BHTG Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 9.59 37.67 1.37
2018-12-31 10.82 37.45 2.41
2018-09-30 3.80 5.80 0.38
2018-06-30 4.97 5.72 1.05
2018-03-31 1.29 10.87 3.22
2017-12-31 -10.39 16.74 0.90
2017-09-30 -16.14 16.70 0.48
2017-06-30 -14.47 14.48 0.15
2017-03-31 -13.11 13.52 0.32
2016-12-31 -11.46 11.53 0.33
2016-09-30 -9.90 9.41 0.18
2016-06-30 -8.42 8.48 0.23
2016-03-31 -6.92 7.28 0.14
2015-12-31 -5.45 5.34 0.04
2015-09-30 -6.15 6.69 0.05
2015-06-30 -4.70 6.01 0.04
2015-03-31 -3.15 4.42 0.04
2014-12-31 -3.15 4.42 0.04
2014-09-30
2014-06-30 -0.03 0.03 0.00
2014-03-31 -0.32 2.45 0.29
2013-12-31 -0.32 2.45 0.29
  • BioHiTech Global's level of debt (392.6%) compared to net worth is high (greater than 40%).
  • BioHiTech Global had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • BioHiTech Global has less than a year of cash runway based on current free cash flow.
  • BioHiTech Global has less than a year of cash runway if free cash flow continues to grow at historical rates of 23% each year.
X
Financial health checks
We assess BioHiTech Global's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BioHiTech Global has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is BioHiTech Global's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BioHiTech Global dividends.
If you bought $2,000 of BioHiTech Global shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BioHiTech Global's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BioHiTech Global's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:BHTG Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
United States of America Commercial Services Industry Average Dividend Yield Market Cap Weighted Average of 41 Stocks 1.6%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:BHTG Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BioHiTech Global has not reported any payouts.
  • Unable to verify if BioHiTech Global's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BioHiTech Global's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BioHiTech Global has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess BioHiTech Global's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BioHiTech Global afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BioHiTech Global has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of BioHiTech Global's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Frank Celli
COMPENSATION $410,400
AGE 49
TENURE AS CEO 3.9 years
CEO Bio

Mr. Frank E. Celli has been the Chief Executive Officer of BioHiTech Global, Inc. since August 06, 2015 and serves as its Chairman of the Board. Mr. Celli joined BioHiTech America in 2008. Mr. Celli serves as the Chief Executive Officer of Highstar Waste Holding Corp. He serves as an Officer of Entsorga West Virginia. With over 25 years of Waste Industry experience, Mr. Celli has leveraged his knowledge of the traditional waste industry to facilitate the development of the Eco-Safe Digester and BioHiTech Cloud to begin the transformation of the organic waste industry. He was Co-Founder and served as Chief Executive Officer of Interstate Waste Services from October 2000 to November 2006. During his time at Interstate Waste, he was responsible for all aspects of the business including collection, recycling, landfills and emerging technologies. He has been Director of BioHiTech Global, Inc. since August 06, 2015. He also serves as a Director of Entsorga West Virginia. Mr. Celli is also the chairman of the board of Apple Valley Waste Services, Inc. Mr. Celli earned a Bachelors of Science from Pace University’s Lubin School of Business in 1992.

CEO Compensation
  • Frank's compensation has increased whilst company is loss making.
  • Frank's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the BioHiTech Global management team in years:

3.7
Average Tenure
54.5
Average Age
  • The tenure for the BioHiTech Global management team is about average.
Management Team

Frank Celli

TITLE
Chairman & CEO
COMPENSATION
$410K
AGE
49
TENURE
3.9 yrs

Bob Joyce

TITLE
Chief Operating Officer
COMPENSATION
$679K
AGE
60
TENURE
1.5 yrs

Brian Essman

TITLE
Chief Financial Officer
COMPENSATION
$504K
AGE
60
TENURE
3.7 yrs

Bill Kratzer

TITLE
Chief Technology Officer
COMPENSATION
$279K
AGE
46
TENURE
5.8 yrs

Lisa Giovannielli

TITLE
Marketing Director

Mike Franco

TITLE
Vice President of Sales

Dennis Soriano

TITLE
Director of Business Development and Strategic Relationships
TENURE
3.3 yrs

Richard Galterio

TITLE
Executive Vice President
Board of Directors Tenure

Average tenure and age of the BioHiTech Global board of directors in years:

3.9
Average Tenure
61.5
Average Age
  • The tenure for the BioHiTech Global board of directors is about average.
Board of Directors

Frank Celli

TITLE
Chairman & CEO
COMPENSATION
$410K
AGE
49

James Chambers

TITLE
Independent Director
COMPENSATION
$74K
AGE
62
TENURE
11 yrs

Bob Graham

TITLE
Independent Director
COMPENSATION
$74K
AGE
60
TENURE
5.8 yrs

Tony Fuller

TITLE
Independent Director
COMPENSATION
$74K
AGE
61
TENURE
2.4 yrs

Doug VanOort

TITLE
Independent Director
COMPENSATION
$74K
AGE
64
TENURE
3.9 yrs

Harriet Hentges

TITLE
Independent Director
COMPENSATION
$74K
AGE
78
TENURE
3.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess BioHiTech Global's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BioHiTech Global has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Do Institutions Own BioHiTech Global, Inc. (NASDAQ:BHTG) Shares?

View our latest analysis for BioHiTech Global NasdaqCM:BHTG Ownership Summary, May 22nd 2019 What Does The Institutional Ownership Tell Us About BioHiTech Global? … Insider Ownership Of BioHiTech Global The definition of company insiders can be subjective, and does vary between jurisdictions. … Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company.

Simply Wall St -

BioHiTech Global, Inc. (NASDAQ:BHTG): Are Analysts Optimistic?

BioHiTech Global, Inc.'s (NASDAQ:BHTG):. … BioHiTech Global, Inc., through its subsidiaries, provides technological, biological, and mechanical engineering solutions for the control, reduction, and/or reuse of organic waste in the United States and internationally. … See our latest analysis for BioHiTech Global

Simply Wall St -

What Percentage Of BioHiTech Global, Inc. (NASDAQ:BHTG) Shares Do Insiders Own?

(NASDAQ:BHTG), then you'll have to look at the makeup of its share registry. … As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.'. … Taking a look at our data on the ownership groups (below), it's seems that.

Simply Wall St -

Should You Worry About BioHiTech Global Inc's (NASDAQ:BHTG) CEO Pay?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … According to our data, BioHiTech Global Inc has a market capitalization of US$38m, and pays its CEO total annual compensation worth US$486k. … As you can see, Frank Celli is paid more than the median CEO pay at companies of a similar size, in the same market

Simply Wall St -

What Kind Of Shareholders Own BioHiTech Global Inc (NASDAQ:BHTG)?

A look at the shareholders of BioHiTech Global Inc (NASDAQ:BHTG) can tell us which group is most powerful. … BioHiTech Global is a smaller company with a market capitalization of US$44m, so it may still be flying under the radar of many institutional investors. … institutional investors have not yet purchased much of the company.

Simply Wall St -

BioHiTech Global Inc (NASDAQ:BHTG): Time For A Financial Health Check

While small-cap stocks, such as BioHiTech Global Inc (NASDAQ:BHTG) with its market cap of US$60.54m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn. … the current state of its operations and pathway to profitability.

Simply Wall St -

Have Investors Priced In BioHiTech Global Inc's (NASDAQ:BHTG) Growth?

BioHiTech Global Inc (NASDAQ:BHTG), a commercial services company based in United States,. … As a small cap stock, hardly covered by any analysts, there is generally more of an opportunity for mispricing as there is less activity to push the stock closer to fair value? … Let’s take a look at BioHiTech Global’s outlook and value based on the most recent financial data to see if the opportunity still exists

Simply Wall St -

When Will BioHiTech Global Inc (NASDAQ:BHTG) Become Profitable?

With the latest financial year loss of -US$8.35m and a trailing-twelve month of -US$11.63m, the US$54.92m market-cap amplifies its loss by moving further away from its breakeven target? … I’ve put together a brief outline of industry analyst expectations for BHTG, its year of breakeven and its implied growth rate … According to the industry analysts covering BHTG, breakeven is near.

Simply Wall St -

Before You Buy BioHiTech Global Inc's (NASDAQ:BHTG), Consider This

A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … BHTG, with its market capitalisation of US$53.47M, is a small-cap stock, which generally have higher beta than similar companies of larger size. … An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive.

Simply Wall St -

Should You Wait Before Investing In BioHiTech Global Inc (NASDAQ:BHTG)?

NasdaqCM:BHTG Income Statement May 9th 18 When will BioHiTech Global need to raise more cash? … Not surprisingly, if BioHiTech Global continues to ramp up expenditure at this rate for the upcoming year, it’ll likely need to come to market within the next few months, given the its current level of cash reserves. … The cash burn analysis result indicates a cash constraint for the company, due to its high opex growth and its level of cash reserves.

Simply Wall St -

Company Info

Description

BioHiTech Global, Inc., through its subsidiaries, provides technological, biological, and mechanical engineering solutions for the control, reduction, and/or reuse of organic and municipal waste worldwide. The company sells, rents, services, and maintains digesters, which are a data-driven network-based mechanical/biological technology that transforms food waste into nutrient-neutral water that could be disposed of through conventional sanitary sewer systems under the Revolution Series Digester and Eco-Safe Digester names. Its digesters process organic food waste, including vegetables, fruits, meat, fish, poultry, grains, coffee grinds, egg shells, and dairy products. The company also provides BioHiTech Cloud, Cirrus, and Alto mobile applications for digester customers. Its principal customers include producers of food waste. The company serves healthcare, grocery, prison, retail food service, and hospitality industries, as well as governments, conference centers, education centers, and stadiums. BioHiTech Global, Inc. is headquartered in Chestnut Ridge, New York.

Details
Name: BioHiTech Global, Inc.
BHTG
Exchange: NasdaqCM
Founded:
$26,834,320
14,907,956
Website: http://www.biohitech.com
Address: BioHiTech Global, Inc.
80 Red Schoolhouse Road,
Suite 101,
Chestnut Ridge,
New York, 10977,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM BHTG Common Shares Nasdaq Capital Market US USD 18. Aug 2015
Number of employees
Current staff
Staff numbers
27
BioHiTech Global employees.
Industry
Environmental and Facilities Services
Commercial Services
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/22 03:09
End of day share price update: 2019/07/19 00:00
Last estimates confirmation: 2019/05/22
Last earnings filing: 2019/05/15
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.